These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2125857

  • 1. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N.
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [Abstract] [Full Text] [Related]

  • 2. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin.
    Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N.
    Acta Psychiatr Scand; 1991 Apr; 83(4):244-8. PubMed ID: 1903019
    [Abstract] [Full Text] [Related]

  • 3. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin.
    Miller CH, Fleischhacker WW, Ehrmann H, Kane JM.
    Psychopharmacol Bull; 1990 Apr; 26(3):373-6. PubMed ID: 1980375
    [Abstract] [Full Text] [Related]

  • 4. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.
    Akhondzadeh S, Mohajari H, Reza Mohammadi M, Amini H.
    BMC Psychiatry; 2003 Jun 19; 3():7. PubMed ID: 12816549
    [Abstract] [Full Text] [Related]

  • 5. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam.
    Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ.
    Pharmacopsychiatry; 1985 Sep 19; 18(5):303-5. PubMed ID: 3931107
    [Abstract] [Full Text] [Related]

  • 6. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
    Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH.
    Psychopharmacology (Berl); 2002 Jun 19; 162(1):55-62. PubMed ID: 12107618
    [Abstract] [Full Text] [Related]

  • 7. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
    Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V.
    Pharmacopsychiatry; 1989 Nov 19; 22(6):246-9. PubMed ID: 2616635
    [Abstract] [Full Text] [Related]

  • 8. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
    Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL.
    Br J Psychiatry; 1993 Oct 19; 163():451-5. PubMed ID: 7902766
    [Abstract] [Full Text] [Related]

  • 9. Effects of ritanserin on sleep disturbances of dysthymic patients.
    Paiva T, Arriaga F, Wauquier A, Lara E, Largo R, Leitao JN.
    Psychopharmacology (Berl); 1988 Oct 19; 96(3):395-9. PubMed ID: 3146774
    [Abstract] [Full Text] [Related]

  • 10. Effects of mianserin in neuroleptic-induced parkinsonism.
    Korsgaard S, Friis T.
    Psychopharmacology (Berl); 1986 Oct 19; 88(1):109-11. PubMed ID: 2868480
    [Abstract] [Full Text] [Related]

  • 11. Study to establish the indication for the selective S2 antagonist ritanserin.
    Klieser E, Strauss WH.
    Pharmacopsychiatry; 1988 Nov 19; 21(6):391-3. PubMed ID: 3149751
    [Abstract] [Full Text] [Related]

  • 12. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
    Den Boer JA, Westenberg HG.
    Psychopharmacology (Berl); 1990 Nov 19; 102(1):85-94. PubMed ID: 1697419
    [Abstract] [Full Text] [Related]

  • 13. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
    Bressa GM, Marini S, Gregori S.
    Int J Clin Pharmacol Res; 1987 Nov 19; 7(2):111-9. PubMed ID: 3108171
    [Abstract] [Full Text] [Related]

  • 14. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ, Saniabadi AR, Hosie J, Lowe GD, Ball SG.
    Eur J Clin Pharmacol; 1988 Nov 19; 35(2):123-9. PubMed ID: 3142775
    [Abstract] [Full Text] [Related]

  • 15. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.
    Gerlach J, Rasmussen PT, Hansen L, Kristjansen P.
    Acta Psychiatr Scand; 1977 Apr 19; 55(4):251-60. PubMed ID: 324238
    [Abstract] [Full Text] [Related]

  • 16. Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease.
    Henderson J, Yiannikas C, Graham JS.
    Clin Exp Neurol; 1992 Apr 19; 29():277-82. PubMed ID: 1343870
    [Abstract] [Full Text] [Related]

  • 17. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial.
    Olson WL, Gruenthal M, Mueller ME, Olson WH.
    Am J Med; 1997 Jan 19; 102(1):60-6. PubMed ID: 9209202
    [Abstract] [Full Text] [Related]

  • 18. [Development of new antipsychotic drugs].
    Vanden Bussche G, Gelders YG, Heylen SL.
    Acta Psiquiatr Psicol Am Lat; 1990 Jan 19; 36(1-2):13-25. PubMed ID: 2127339
    [Abstract] [Full Text] [Related]

  • 19. Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
    Merello M, Starkstein S, Petracca G, Cataneo EA, Manes F, Leiguarda R.
    Clin Neuropharmacol; 1996 Oct 19; 19(5):439-43. PubMed ID: 8889287
    [Abstract] [Full Text] [Related]

  • 20. An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.
    Vågen R, Götestam KG.
    Acta Psychiatr Scand; 1986 Nov 19; 74(5):519-23. PubMed ID: 2880460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.